---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-049661"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-07-27T11:01:41+00:00"
generated_at: "2026-07-27T11:05:23.302416+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CAMP4 receives Australian TGA clearance for CMP-002 Phase 1/2 trial; triggers $50M second closing

## Summary
- TGA and HREC clearance to initiate first-in-human Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder.
- Milestone triggers second closing of September 2025 private placement; up to $50M gross proceeds.
- Second closing expected on or about August 3, 2026; up to 32.7M shares (or pre-funded warrants) to be issued.
- Investors committed include Coastlands Capital, Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures, Adage, Trails Edge, CURE SYNGAP1.
- Australia selected as first site; company pursuing additional international regulatory filings.

## SEC filing metadata
- accession: 0001628280-26-049661
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-07-27T11:01:41+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000162828026049661/0001628280-26-049661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000162828026049661/camp-20260727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-049661
- JSON: https://secwatch.observer/filing/0001628280-26-049661.json
- Plain text: https://secwatch.observer/filing/0001628280-26-049661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.